Genitourinary Cancer—Kidney and Bladder

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

 
Maha H. A. Hussain, Thomas Powles, Peter Albers, et al.
 
The abstract concludes: 
IMvigor010, the first phase 3 adjuvant study of a checkpoint inhibitor in MIUC, did not meet its primary EP of DFS. More tx discontinuation due to AEs was seen vs mUC studies. Safety was generally consistent with previous studies. Clinical trial information: NCT02450331.
————————————————————————————————————————————————————————————————————————————
 
 
Elizabeth R. Plimack, Brian I. Rini, Viktor Stus, et al.
 
The abstract concludes: 
Pembro + axi continued to demonstrate superior and durable antitumor activity vs sunitinib in pts with first-line aRCC with a 27-mo median follow up; no new safety signals were observed. Clinical trial information: NCT02853331.
————————————————————————————————————————————————————————————————————————————
 
The abstract concludes: 
Although pt numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy and an improved safety profile vs sunitinib, with fewer grade ≥3 AEs and fewer dose modifications required. Sunitinib performance was poorer than expected based on external retrospective data. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted. Clinical trial information: NCT03091192.
 
Published simultaneously in JAMA Oncology:
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
————————————————————————————————————————————————————————————————————————————
 
The abstract concludes: 
MK-6482 showed promising efficacy and tolerability in pts with VHL-associated ccRCC and responses in other VHL-related lesions. These data support further investigation of MK-6482 in VHL disease. Clinical trial information: NCT03401788.
————————————————————————————————————————————————————————————————————————————
 
 
Ramaprasad Srinivasan, Sandeep Gurram, Munjid Al Harthy, et al.
 
The abstract concludes: 
The combination of bevacizumab and erlotinib is well tolerated and is associated with encouraging activity in advanced pRCC, particularly in patients with FH deficient tumors. This is the first and largest prospective study in HLRCC and provides the basis for considering bevacizumab and erlotinib as a preferred option in a patient population that has no widely accepted standard. Clinical trial information: NCT01130519.
————————————————————————————————————————————————————————————————————————————
 
 
Rana R. McKay, Wanling Xie, Bradley Alexander McGregor, et al. 
 
The abstract concludes: 
We cannot currently recommend a strategy of Nivo followed by response-based addition of Ipi due to the absence of CR and low PR/CR conversion rate (4%). Though a subset of pts treated with Nivo alone can maintain durable responses off tx at 1-yr, early Nivo discontinuation in the absence of toxicity cannot currently be recommended. Investigation into biomarkers to guide tx is ongoing. Clinical trial information: NCT03203473.
————————————————————————————————————————————————————————————————————————————
 
 
Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, et al. 
 
The abstract concludes: 
Nivo monotherapy is active in treatment naïve ccRCC across all IMDC groups. Toxicity is consistent with prior nivo studies. Salvage treatment with nivo/ipi after nivo monotherapy was feasible in 53% of pts with PD/pSD, with 11% responding. Clinical trial information: NCT03117309.
————————————————————————————————————————————————————————————————————————————
 
 
Toni K. Choueiri, Harriet M. Kluger, Saby George, et al. 
 
The abstract concludes: 
These results suggest that NIVO+IPI may provide durable partial response in some pts with prior progression on checkpoint inhibitors, including some heavily pretreated pts. The safety profile of NIVO+IPI in FRACTION pts was similar to historic data in aRCC with this combination. Clinical trial information: NCT02996110.
 
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
 
 
Chung-Han Lee, Amishi Yogesh Shah, James J Hsieh, et al.
 
The abstract concludes: 
LEN + PEMBRO demonstrated promising antitumor activity in pts with mccRCC with disease progression following ICI therapy. No new safety signals were detected. Efficacy outcomes by investigator review per irRECIST. Clinical trial information: NCT02501096.
————————————————————————————————————————————————————————————————————————————
 
 
DISCUSSANT
Sumanta K. Pal, MD | City of Hope Comprehensive Cancer Center

————————————————————————————————————————————————————————————————————————————

Read the comment By Dr. Matthew T. Campbell and Dr. Amishi Y. Shah in the ASCO DAILY NEWS (Pivotal studies in the last 2 years mentioned, including Javelin Renal 101, CheckMate-214, and Keynote-426):

Therapeutic Options for Metastatic Clear Cell Renal Cell Carcinoma: The Front Line and Beyond in Early 2020

————————————————————————————————————————————————————————————————————————————
 
MORE ABSTRACTS:
 
Poster Discussion Session
 
Poster Session
 
ASCO Direct™ Focus – ASCO®20 Virtual Program  
Top presentations and expert interviews now available on demand!
Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology"  
ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries.
Genitourinary (Abstracts #LBA1, 5001, 5006)
Access Content Now